The Online Investor
Prevail Therapeutics Inc (PRVL)

Prevail Therapeutics is a gene therapy company using discoveries in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Co.'s lead program is PR001 for the treatment of Parkinson's disease with GBA1 mutation, and neuronopathic (Type 2 or Type 3) Gaucher disease. Co. is focused on developing a pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation, or FTD-GRN, and PR004 for the treatment of synucleinopathies.
Company Name: 
Prevail Therapeutics Inc
Quotes delayed 20 minutes

Buy (2.67 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
PRVL Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Prevail Therapeutics Inc (PRVL) Page | The Online Investor Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.